FLT3 and leukemia: CHR rate: 83.3% of patients (20/24) achieved complete remission (true or with insufficient hematological recovery).Reduction in ITD Allelic Burden: Significant reduction of FLT3-ITD allelic burden in patients.OS:Median Leukemia-Free Survival: 12 weeks.Median Overall Survival: 33 weeks.